BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xu W, Ye C, Qing X, Liu S, Lv X, Wang W, Dong X, Zhang Y. Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy. Mater Today Bio 2022;16:100358. [PMID: 35880099 DOI: 10.1016/j.mtbio.2022.100358] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
Number Citing Articles
1 Brar HK, Jose J, Wu Z, Sharma M. Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery. Pharmaceutics 2022;15. [PMID: 36678688 DOI: 10.3390/pharmaceutics15010059] [Reference Citation Analysis]
2 Andreeva OE, Sorokin DV, Scherbakov AM, Shchegolev YY, Gudkova MV, Krasil’nikov MA. MicroRNA-484 / Akt axis in the regulation of breast cancer cells sensitivity to antitumor drugs. Usp mol onkol 2022;9:112-116. [DOI: 10.17650/2313-805x-2022-9-4-112-116] [Reference Citation Analysis]
3 Lee HW, Seo HS, Yeom S, Kim S, Kim CR, Park D, Park W, Choy YB, Park CG, Seo SI. Cabozantinib-Loaded PLGA Nanoparticles: A Potential Adjuvant Strategy for Surgically Resected High-Risk Non-Metastatic Renal Cell Carcinoma. IJMS 2022;23:12634. [DOI: 10.3390/ijms232012634] [Reference Citation Analysis]
4 Xu W, Xu L, Jia W, Mao X, Liu S, Dong H, Zhang H, Zhang Y. Nanomaterials based on phase change materials for antibacterial application. Biomater Sci 2022. [DOI: 10.1039/d2bm01220k] [Reference Citation Analysis]